Intralesional corticosteroid injections for infantile hemangioma  

作　　者：Rui Chang Yajing Qiu Xiaoxi Lin 

机构地区：[1]Department of Plastic and Reconstructive Surgery,Shanghai Ninth People’s Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200011,China

出　　处：《Chinese Journal of Plastic and Reconstructive Surgery》2023年第2期80-85,共6页

基　　金：supported by the National Nature Science Foundation of China (grant no. 82272288)。

摘　　要：Infantile hemangiomas(IHs) are the most common benign soft-tissue tumors in infancy;about 10%–15% of them may result in various complications that require active management. The current first-line treatment for IH is oral propranolol;however, some studies recommend intralesional corticosteroid injections for small, limited, deep, or prominent tumors because of concern regarding serious systemic complications related to propranolol. This review summarizes and analyzes the current clinical studies on corticosteroid injections in IHs, discusses treatment norms, and explores future research directions.

关 键 词：Infantile hemangioma Intralesional injections CORTICOSTEROIDS Clinical norms BLEOMYCIN PROPRANOLOL LAUROMACROGOL BEVACIZUMAB 

分 类 号：R738.6[医药卫生—肿瘤]